|
KMID : 0378019870300090075
|
|
New Medical Journal
1987 Volume.30 No. 9 p.75 ~ p.82
|
|
|
Effect of Wakamoto-Strong^(®) on Cancer Patients receiving Chemotherapy
|
|
|
|
|
Abstract
|
|
|
The effect of Wakamoto-Strong° (WKM) on the cellular immunity and gastrointestinal symptoms cf patients with cancer were evaluated.
Patients with stomach cancer, receiving FAM chemotherapy, and non-small cell lung cancer, receiving CAP chemotherapy, were devided into two groups, WKM treated group and not treated group (cortrol). Peripheral blood were collected serially just before injection of chemotherapeutic agents. Hemoglobir., hematocrit, serum protein and albumin were measured. Surface markers (with monoclonal antibodies OKT.2 , OKT4, OKT8) of monouclear cells were measured by immunofluroescence methods. ´H-thymidine uptake were measured after PHA or interleukin-2 (1L2) stimulation. Natural killer activities against K562 and cytotoxicities against K562 and RC29 of lymphokine activated killer (LAK) cells, induced by 48 hour incubation of peripheral blood mononuclear cells with 1L2, were measured by 4-hour 51Cr release methods. Gastrointestinal symptoms of the patients (anorexia, nausea, vomiting, abdominal discomfort, constipation, diarrhea) for 2 weeks until just before each chemotherpy cycle start were evaluated with grading method: The changes of values after each chemotherapy were evaluated and compared in two groups. The results were as follows:
The proportions of OKT3 and OKT8 positive cells were not changed after chemotherapy. OKT4 positive cells were increased in WKM treated group, but there was no significant difference between the two groups.
In both groups, 3H-thymidine uptake after PHA stimulation was decreased, natural killer activity were not changed, ´H-thymidine uptake after incubation with IL2 were not changed, and cytotoxicities of LAK cells against RC29 and K562 were increased, after chemotherapy. But there were no significant difference between the two groups.
Hemoglobin levels decreased but serum protein level were not changed after chemotherapy in both groups. Serum albumin levels and body weight decreased in control group but not in WKM treated group. There was significant differnce in changes of serum albumin level between the two groups. Among the gastrointestinal symptoms, aggravation of anorexia, nausea, vomiting were same in two groups, but ag gravation of abdominal discomfort, constipation, and diarrhea were less severe in WKM treated group.
With oral administration of WKM, cellular immunity was not enhanced but gastrointestinal symptoms were less aggravated. Further investigation about the effective portion of WKM which has anticancer effect and development of administration method of this drug may be necessary.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|